

Young-Jae Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/745020/publications.pdf>

Version: 2024-02-01

18
papers

200
citations

1307594

7
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

397
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e32.	2.2	44
2	A postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection. <i>Gynecologic Oncology</i> , 2017, 144, 536-540.	1.4	26
3	Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline <i>BRCA</i> mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline <i>BRCA</i> mutation carriers. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e3.	2.2	22
4	Feasibility of uterine preservation in the management of early-stage uterine adenosarcomas: a single institute experience. <i>World Journal of Surgical Oncology</i> , 2017, 15, 87.	1.9	20
5	Correlation between postpartum depression and premenstrual dysphoric disorder: Single center study. <i>Obstetrics and Gynecology Science</i> , 2015, 58, 353.	1.6	19
6	Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e8.	2.2	11
7	Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study. <i>Frontiers in Oncology</i> , 2021, 11, 636378.	2.8	9
8	Single-Incision versus Multiport Robotic Myomectomy: A Propensity Score Matched Analysis of Surgical Outcomes and Surgical Tips. <i>Journal of Clinical Medicine</i> , 2021, 10, 3957.	2.4	9
9	Diagnostic value of integrated ¹⁸ F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e36.	2.2	8
10	Successful management of maternal factor VII deficiency in a cesarean section. <i>Obstetrics and Gynecology Science</i> , 2014, 57, 314.	1.6	7
11	New Surgical Technique for Robotic Myomectomy: Continuous Locking Suture on Myoma (LSOM) Technique. <i>Journal of Clinical Medicine</i> , 2021, 10, 654.	2.4	6
12	Robot-Assisted Laparoscopic Myomectomy versus Abdominal Myomectomy for Large Myomas Sized over 10 cm or Weighing 250 g. <i>Yonsei Medical Journal</i> , 2020, 61, 1054.	2.2	6
13	Performance evaluation of an amplicon-based next-generation sequencing panel for BRCA1 and BRCA2 variant detection. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23524.	2.1	4
14	Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9638.	4.1	4
15	Comparison of Risk of Ovarian Malignancy Algorithm and cancer antigen 125 to discriminate between benign ovarian tumor and early-stage ovarian cancer according to imaging tumor subtypes. <i>Oncology Letters</i> , 2020, 20, 931-938.	1.8	4
16	The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 433.	1.6	1
17	Pathologic findings at risk-reducing salpingo-oophorectomy in germline <i>BRCA</i> mutation carriers: Optimal age of bilateral RRSO.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13046-e13046.	1.6	0
18	Abstract 6185: Combining PARP inhibitor with cMET Inhibition overcomes PARP inhibitor resistance in epithelial ovarian cancer. <i>Cancer Research</i> , 2022, 82, 6185-6185.	0.9	0